A Study to Assess the Effects of MK0812 on Disease Activity in Patient
A Randomized, Double-Blind Placebo Controlled, Parallel Groups Study to Assess the Effects of MK0812 on Disease Activity in Patients With Relapsing-Remitting Multiple Sclerosis as Measured by MRI
What it found
The trial ended early for another reason (see below).
This trial finished 20 years ago. We found no results in the registry or in any paper that cites it.
What was tested
Treatment tested
- Mk-0812
C-C chemokine receptor type 2 antagonist
What it measured
Main measures
Accrual rate of new GD-enhancing lesions as assessed by MRI
3 Months
MRI lesions
Other measures (1)
Volume and cumulative number of new persistent Gd-enhancing lesions
3 Months
MRI lesions
Who could take part
Relapsing MS · 18 to 55
Show the full criteria
Inclusion criteria
* Patients must have clinically definite relapsing-remitting MS onset within last 10 years and have had at least 1 objective clinical exacerbation in the last year OR a recent clinically isolated syndrome suggestive of MS occurring 3-12 months before screening * Patients must be relatively healthy
Exclusion criteria
* Patient has primary progressive MS
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
The purpose of this study is to test MK0812 on disease activity in patients with relapsing-remitting MS. Disease modifying activity will be assessed by measurement of brain lesions via MRI brain scans and an open label extension is offered.
Papers
Loading reviews and guidelines…
History
Started
Aug 2004
Main results due
Dec 2005
Finished
Jan 2006